# Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

> **NCT00831844** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 116 (actual)

## Conditions studied

- Adult Rhabdomyosarcoma
- Adult Synovial Sarcoma
- Childhood Hepatoblastoma
- Childhood Synovial Sarcoma
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Adrenocortical Carcinoma
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Childhood Liver Cancer
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Ewing Sarcoma/Peripheral Primitive
- Neuroectodermal Tumor
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma
- Recurrent Retinoblastoma
- Recurrent Wilms Tumor and Other Childhood Kidney Tumors

## Interventions

- **BIOLOGICAL:** cixutumumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00831844
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2013-04
- **Final completion:** 2013-10
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2015-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00831844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00831844, "Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00831844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*